U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H35N3O6S
Molecular Weight 505.627
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMPRENAVIR

SMILES

CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)S(=O)(=O)C3=CC=C(N)C=C3

InChI

InChIKey=YMARZQAQMVYCKC-OEMFJLHTSA-N
InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1

HIDE SMILES / InChI

Molecular Formula C25H35N3O6S
Molecular Weight 505.627
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23519392 | https://www.ncbi.nlm.nih.gov/pubmed/11152018 | https://www.ncbi.nlm.nih.gov/pubmed/15341507

Amprenavir is an inhibitor of HIV-1 protease. Amprenavir binds to the active site of HIV-1 protease and thereby prevents the processing of viral gag and gag-pol polyprotein precursors, resulting in the formation of immature non-infectious viral particles. Amprenavir-containing combination regimens have shown virological efficacy, and have generally been well tolerated, in patients with HIV infection (primarily treatment-naive or protease inhibitor-naive). Fosamprenavir (GW433908, Lexiva, Telzir) is an oral prodrug of amprenavir, with a reduced daily pill burden. The use of protease inhibitors has also been associated with dyslipidemia and an increased risk of cardiovascular disease. Amprenavir activates Pregnane X receptor to mediate dyslipidemia.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AGENERASE

Approved Use

AGENERASE (amprenavir) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.36 μg/mL
1200 mg 2 times / day multiple, oral
dose: 1200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.18 μg/mL
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
9.72 μg/mL
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
6.77 μg/mL
20 mg/kg bw 2 times / day multiple, oral
dose: 20 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
3.99 μg/mL
15 mg/kg bw 3 times / day multiple, oral
dose: 15 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
18.5 μg × h/mL
1200 mg 2 times / day multiple, oral
dose: 1200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
22.06 μg × h/mL
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
28.05 μg × h/mL
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
15.46 μg × h/mL
20 mg/kg bw 2 times / day multiple, oral
dose: 20 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
8.73 μg × h/mL
15 mg/kg bw 3 times / day multiple, oral
dose: 15 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.85 h
1200 mg 2 times / day multiple, oral
dose: 1200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
1200 mg 2 times / day multiple, oral
dose: 1200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources: Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources: Page: p.1387
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (12%)
Vomiting (6%)
Loose stools (3%)
Abdominal pain (2%)
Abdominal discomfort (2%)
Rash (3%)
Sources: Page: p.1387
1200 mg single, oral
Recommended
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources: Page: p.1688
unhealthy, 33+/-6.7
n = 12
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 33+/-6.7
Sex: M+F
Population Size: 12
Sources: Page: p.1688
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.11
Disc. AE: Reaction skin, Stevens-Johnson syndrome...
AEs leading to
discontinuation/dose reduction:
Reaction skin (grade 3-4)
Stevens-Johnson syndrome (grade 3-4)
Sources: Page: p.11
AEs

AEs

AESignificanceDosePopulation
Nausea 12%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources: Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources: Page: p.1387
Abdominal discomfort 2%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources: Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources: Page: p.1387
Abdominal pain 2%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources: Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources: Page: p.1387
Loose stools 3%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources: Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources: Page: p.1387
Rash 3%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources: Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources: Page: p.1387
Vomiting 6%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources: Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources: Page: p.1387
Reaction skin grade 3-4
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.11
Stevens-Johnson syndrome grade 3-4
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.11
PubMed

PubMed

TitleDatePubMed
Four new antiretroviral medications will soon offer more options to HIV patients.
1998 Jul-Aug
Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
2001
Principles and practice of HIV-protease inhibitor pharmacoenhancement.
2001 Apr
Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.
2001 Apr
A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir.
2001 Apr 15
A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.
2001 Apr 15
Liquid chromatographic-tandem mass spectrometric determination of amprenavir (agenerase) in serum/plasma of human immunodeficiency virus type-1 infected patients receiving combination antiretroviral therapy.
2001 Apr 20
Antiviral drugs: current state of the art.
2001 Aug
Genotypic correlates of resistance to HIV-1 protease inhibitors on longitudinal data: the role of secondary mutations.
2001 Dec
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
2001 Dec
Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection.
2001 Dec
Safety profile and tolerability of amprenavir in patients enrolled in an early access program.
2001 Feb
Structure-based design of non-peptide HIV protease inhibitors.
2001 Jan-Feb
Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac.
2001 Jul
Synthesis of a chiral aziridine derivative as a versatile intermediate for HIV protease inhibitors.
2001 Jul 26
Amprenavir: new preparation. Another HIV protease inhibitor: no proven advance.
2001 Jun
A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
2001 Jun
Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV.
2001 Mar
Phase III trials for new PI.
2001 Mar
Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.
2001 Mar 30
Resistant to everything.
2001 May
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
2001 May 25
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.
2001 May 5
From amprenavir to GW433908.
2001 Nov
DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.
2001 Nov
New developments in anti-HIV chemotherapy.
2001 Nov
Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
2001 Nov 23
Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.
2001 Oct
Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist.
2002
New dosing regimen approved.
2002 Apr
Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography.
2002 Apr
In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
2002 Feb
A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.
2002 Feb
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
2002 Feb 15
Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.
2002 Feb 22
Clinical pharmacology and pharmacokinetics of amprenavir.
2002 Jan
Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.
2002 Jan 17
Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitors in patients developing HAART failure.
2002 Jul
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
2002 Jul 10
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).
2002 Jul 15
Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery.
2002 Jul 15
Synthesis and antiviral activity of new anti-HIV amprenavir bioisosteres.
2002 Jul 18
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
2002 Jun
Lipodystrophy update.
2002 Mar
Efavirenz-induced skin eruption and successful desensitization.
2002 Mar
Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
2002 Mar 29
Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.
2002 Mar 29
Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.
2002 May 1
Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
2002 May 31
Therapeutic vaccination in primary HIV infection, the Quest trial.
2002 May 6
Patents

Sample Use Guides

Adults: The recommended oral dose of AGENERASE Capsules for adults is 1200 mg (eight 150-mg capsules) twice daily in combination with other antiretroviral agents. Concomitant Therapy: If AGENERASE and ritonavir are used in combination, the recommended dosage regimens are: AGENERASE 1200 mg with ritonavir 200 mg once daily or AGENERASE 600 mg with ritonavir 100 mg twice daily. Pediatric Patients: For adolescents (13 to 16 years), the recommended oral dose of AGENERASE Capsules is 1200 mg (eight 150-mg capsules) twice daily in combination with other antiretroviral agents. For patients between 4 and 12 years of age or for patients 13 to 16 years of age with weight of <50 kg, the recommended oral dose of AGENERASE Capsules is 20 mg/kg twice daily or 15 mg/kg 3 times daily (to a maximum daily dose of 2400 mg) in combination with other antiretroviral agents.
Route of Administration: Oral
The in vitro antiviral activity of amprenavir was evaluated against HIV-1 IIIB in both acutely and chronically infected lymphoblastic cell lines (MT-4, CEM-CCRF, 43 H9) and in peripheral blood lymphocytes. The 50% inhibitory concentration (IC50) of amprenavir ranged from 0.012 to 0.08 µM in acutely infected cells and was 0.41 µM in chronically infected cells (1 µM = 0.50 mcg/mL).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:48:47 GMT 2023
Edited
by admin
on Fri Dec 15 15:48:47 GMT 2023
Record UNII
5S0W860XNR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMPRENAVIR
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
AMPRENAVIR [EMA EPAR]
Common Name English
VX-478
Code English
AMPRENAVIR [VANDF]
Common Name English
AMPRENAVIR [MART.]
Common Name English
KVX-478
Code English
(3S-(3R*(1R*,2S*)))-(3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL) TETRAHYDRO-3-FURANYL CARBAMATE
Common Name English
AMPRENAVIR [MI]
Common Name English
AMPRENAVIR [HSDB]
Common Name English
141W94
Code English
AMPRENAVIR [ORANGE BOOK]
Common Name English
J05AE05
Code English
AMPRENAVIR [USAN]
Common Name English
AGENERASE
Brand Name English
AMPRENAVIR [JAN]
Common Name English
Amprenavir [WHO-DD]
Common Name English
amprenavir [INN]
Common Name English
141W94
Code English
(3S)-Tetrahydro-3-furyl [(αS)-α-[(1R-1-hydroxy-2-(N1-isobutylsulfanilamido)ethyl]phenethyl]carbamate
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS AGENERASE (WITHDRAWN: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
WHO-ATC J05AE05
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
NDF-RT N0000175889
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
NCI_THESAURUS C97366
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
NDF-RT N0000000246
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
WHO-VATC QJ05AE05
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
LIVERTOX NBK548011
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
Code System Code Type Description
NDF-RT
N0000182141
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
DAILYMED
5S0W860XNR
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
NDF-RT
N0000185506
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY Cytochrome P450 3A4 Inducers [MoA]
DRUG CENTRAL
200
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
MESH
C095108
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
RXCUI
228656
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY RxNorm
PUBCHEM
65016
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
NCI_THESAURUS
C28824
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
INN
7751
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
EPA CompTox
DTXSID5046061
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
DRUG BANK
DB00701
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
CHEBI
40050
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
USAN
JJ-94
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
ChEMBL
CHEMBL116
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
WIKIPEDIA
AMPRENAVIR
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
FDA UNII
5S0W860XNR
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
MERCK INDEX
m1855
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY Merck Index
NDF-RT
N0000191264
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY P-Glycoprotein Inducers [MoA]
CAS
161814-49-9
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
SMS_ID
100000089388
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
EVMPD
SUB00511MIG
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
HSDB
7157
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
BINDER->LIGAND
The high affinity binding protein for amprenavir is alpha1-acid glycoprotein (AAG).
BINDING
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
EXCRETED UNCHANGED
URINE
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
TARGET ORGANISM->INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
IN VITRO
METABOLITE -> PARENT
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC SINGLE DOSE

ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC